早期T细胞前体急性淋巴细胞白血病的遗传基础
Jinghui Zhang1, Li Ding, Linda Holmfeldt
1Department of Computational Biology and Bioinformatics, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Nature
|January 13, 2012
概括
早期T细胞前体急性淋巴细胞白血病 (ETP ALL) 是一种侵袭性癌症. 基因分析揭示了细胞因子受体,RAS信号传递和发育基因的突变,这表明骨髓细胞导向疗法可能会改善结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 早期T细胞前体急性淋巴细胞白血病 (ETP ALL) 是一种具有未知的遗传基础的侵袭性恶性瘤.
- 了解ETP ALL的遗传环境对于开发向疗法至关重要.
研究的目的:
- 为了确定ETP ALL背后的基因突变.
- 探索基于已识别的基因变异的潜在治疗策略.
主要方法:
- 12个ETP ALL病例的全基因组测序.
- 在另外94例T细胞急性淋巴细胞白血病病例中评估突变频率.
- 分析全球的转录形状.
主要成果:
- 在ETP ALL中经常存在激活细胞因子受体和RAS信号通路 (67%) 的突变,包括NRAS,KRAS,FLT3,IL7R,JAK3,JAK1,SH2B3和BRAF.
- 还确定了破坏造血发育 (58%) 和基因基因基因 (48%) 的非活化病变,包括GATA3,ETV6,RUNX1,IKZF1,EP300,EZH2,EED,SUZ12和SETD2.2.等基因.
- 发现了新的反复突变目标,如DNM2,ECT2L和RELN. 突变谱和转录特征类似于髓状瘤和造血干细胞.
结论:
- ETP ALL表现出一个独特的突变谱,涉及细胞因子受体,RAS信号发送,造血发育和基因基因修饰基因.
- 与骨髓状瘤的遗传和转录相似性表明,骨髓状瘤导向疗法可能是有益的.
- 针对这些途径可能为改善ETP ALL的预后提供新的途径.
相关概念视频
Lineage Commitment
Commitment is the process whereby stem cells:
Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Cells of the Adaptive Immune Response
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


